Feed RLFTY
RL

MindMaze Therapeutics Holding S.A. RLFTY · OTC

$0.18 +0.00% (+$0.00)

Summary

18 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: $6.62M against $29.8K.

What to watch

  • Revenue fell by 53% a year over the last 3 years.
  • The company made a loss over the last 12 months.
  • It passes only 0 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (CHF)

Diluted EPS (CHF)

  • Analyst estimate

Revenue fell by 53% a year over the last 3 years.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of CHF 14.2M.

Profitability in detail

Is it financially healthy?

Yes

Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

Fiscal year 2023

By product

By region

Product Sales brings in 75% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy